Dr. Chatwal earned her MD at Florida State University School of Medicine. She completed her Internal Medicine Residency at Emory University School of Medicine, followed by a Hematology Oncology Fellowship at Moffitt Cancer Center and the University of South Florida Morsani College of Medicine. Dr. Chatwal’s clinical focus is the medical oncology management of patients with genitourinary malignancies, particularly prostate cancer. Her research focus is on prostate cancer clinical trials and outcomes. Dr. Chatwal also has a practical and research interest in the important issue of provider burnout. She has published data on approaches to improve individual resiliency and will explore both individual and system-dependent approaches to help combat and alleviate this ongoing issue. Dr. Chatwal has a part-time appointment at the James A. Haley VA in Tampa as the lead for PoPCaP, the precision oncology in prostate cancer program, to help expand clinical trial access for prostate cancer patients.
- Chatwal MS, Kamal AH, Marron JM. Fear of Saying No (FOSNO): Setting Boundaries With Our Patients and Ourselves. Am Soc Clin Oncol Educ Book. 2023 May.43:e390598. Pubmedid: 37253213.
- Chatwal MS, Chahoud J, Spiess PE. Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma. Cancer Drug Resist. 2023 May.6(2):314-326. Pubmedid: 37457132. Pmcid: PMC10344725.
- Zhang J, Gallaher J, Cunningham JJ, Choi JW, Ionescu F, Chatwal MS, Jain R, Kim Y, Wang L, Brown JS, Anderson AR, Gatenby RA. A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers (Basel). 2022 Oct.14(21). Pubmedid: 36358643. Pmcid: PMC9656891.
- Martin RL, Grant MJ, Kimani S, Midha S, May J, Patell R, Collier E, Furfaro D, Bodine C, Reap L, Shah N, DeLaune J, Brusca S, Olazagasti C, Goyal S, Rubinstein S, Hakim N, Qin S, Browning SL, Sena L, Gilbert J, Davidson M, Lovly CM, Seetharamu N, Rangachari D, Murphy M, Chatwal M, Paschal R, Henry E, Collichio F, Green JR. Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. JCO Oncol Pract. 2022 Jan.18(1):e36-e46. Pubmedid: 34242082. Pmcid: PMC8758064.
- Marji N, Dhillon J, Lauwers GY, Feuerlein S, Nikfar R, Chatwal M, Vosoughi A. Colonic Adenocarcinoma with Plasmacytoid Feature: Histopathology and Molecular Characteristics of a Rare Neoplasm with an Unusual Presentation. Case Rep Pathol. 2022 Feb.2022:2640456. Pubmedid: 35178262. Pmcid: PMC8847023.
- Hlubocky FJ, Shanafelt TD, Back AL, Paice JA, Tetzlaff ED, Friese CR, Kamal AH, McFarland DC, Lyckholm L, Gallagher CM, Chatwal M, Saltzman J, Dudzinski D, Burke JM, James TA, Page RD, Boyle DA, Gonzalez MM, Srivastava P. Creating a Blueprint of Well-Being in Oncology: An Approach for Addressing Burnout From ASCO's Clinician Well-Being Taskforce. Am Soc Clin Oncol Educ Book. 2021 Jun.41:e339-e353. Pubmedid: 34061565.
- Bui KM, Zhang H, Boac BM, Chatwal MS, Dhillon J. Pathology of Seminoma Coinciding With Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. Cureus. 2021 Jul.13(7):e16509. Pubmedid: 34430123. Pmcid: PMC8374996.
- Hlubocky FJ, Taylor LP, Marron JM, Spence RA, McGinnis MM, Brown RF, McFarland DC, Tetzlaff ED, Gallagher CM, Rosenberg AR, Popp B, Dragnev K, Bosserman LD, Dudzinski DM, Smith S, Chatwal M, Patel MI, Markham MJ, Levit K, Bruera E, Epstein RM, Brown M, Back AL, Shanafelt TD, Kamal AH. A Call to Action: Ethics Committee Roundtable Recommendations for Addressing Burnout and Moral Distress in Oncology. JCO Oncol Pract. 2020 Apr.16(4):191-199. Pubmedid: 32223701. Pmcid: PMC7351333.
- Chatwal MS, Tanvetyanon T. Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?. Transl Lung Cancer Res. 2018 Sep.7(Suppl 3):S208-S210. Pubmedid: 30393603. Pmcid: PMC6193911.
- Chatwal MS, Tanvetyanon T. Malignant mesothelioma clinical trial combines immunotherapy drugs. Immunotherapy. 2018 Apr.10(5):341-344. Pubmedid: 29473471.
- Puri S, Chatwal M, Gray JE. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Expert Rev Respir Med. 2017 Oct.11(10):791-805. Pubmedid: 28786318.
GrantsTitle: IRONMAN: International Registry for Men with Advanced Prostate Cancer
Sponsor: PCCTC (Prostate Cancer Clinical Trial Consortium)
PI: Chatwal, M.
Patient CommentsOverall Satisfaction4.8
139 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.Learn more about our patient satisfaction survey
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.